Efficacy and safety of epirubicin and etoposide combination chemotherapy in advanced hepatocellular carcinoma: A retrospective analysis

Journal of Gastroenterology and Hepatology (Australia)

Volumn 23, Issue 5, 2008, Pages 811-816

  Lee, Jae Lyun ^a   Ryu, Min Hee ^a   Chang, Heung M ^a   Kim, Tae Won ^a   Lee, Sung S ^a   Sym, Sun J ^a   Kim, Min K ^a   Kim, Kang M ^a   Lee, Jung S ^a   Kang, Yoon Koo ^a  

^a University of Ulsan College of Medicine   (South Korea)

Author keywords

Chemotherapy; Epirubicin; Etoposide; Hepatocellular carcinoma

Indexed keywords

CISPLATIN; EPIRUBICIN; ETOPOSIDE; HEPATITIS B SURFACE ANTIGEN;

ADULT; ADVANCED CANCER; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANEMIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; ASTHENIA; BLOOD TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CANCER CONTROL; CHEMOEMBOLIZATION; CLINICAL ARTICLE; DIARRHEA; DISEASE ASSOCIATION; DRUG EFFICACY; DRUG SAFETY; FEBRILE NEUTROPENIA; FEMALE; HEPATITIS B VIRUS; HUMAN; LIVER CELL CARCINOMA; MALE; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; PERITONEUM METASTASIS; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SERODIAGNOSIS; SIDE EFFECT; STOMATITIS; SYSTEMIC THERAPY; TREATMENT RESPONSE; VOMITING;

EID: 42049111479     PISSN: 08159319     EISSN: 14401746     Source Type: Journal    
DOI: 10.1111/j.1440-1746.2007.05213.x     Document Type: Article

References (27)

1. Parkin DM, Bray F, Ferlay J, Pisani P. Global Cancer Statistics, 2002. CA Cancer J. Clin. 2005 55 : 74 108.
2. William GC, Andrew KS, Herman RM. The National Cancer Data Base report on treatment patterns for hepatocellular carcinomas. Cancer 2000 88 : 912 20.
3. Okuda K, Ohtsuki T, Obata H et al. Natural history of hepatocellular carcinoma and prognosis in relation to treatment. Study of 850 patients. Cancer 1985 56 : 918 28.
4. Lai CL, Wu PC, Chan GC, Lok AS, Lin HJ. Doxorubicin versus no antitumor therapy in inoperable hepatocellular carcinoma. A prospective randomized trial. Cancer 1988 62 : 479 83.
5. Burroughs A, Hochhauser D, Meyer T. Systemic treatment and liver transplantation for hepatocellular carcinoma: two ends of the therapeutic spectrum. Lancet Oncol. 2004 5 : 409.
6. Mathurin P, Rixe O, Carbonell N et al. Review article: overview of medical treatments in unresectable hepatocellular carcinoma an impossible meta-analysis? Aliment. Pharmacol. Ther. 1998 12 : 111 26.
7. Simonetti RG, Liberati A, Angiolini C, Pagliaro L. Treatment of hepatocellular carcinoma: a systematic review of randomized controlled trials. Ann. Oncol. 1997 8 : 117 36.
8. Ng IO, Liu CL, Fan ST, Ng M. Expression of P-glycoprotein in hepatocellular carcinoma. A determinant of chemotherapy response. Am. J. Clin. Pathol. 2000 113 : 355 63.
9. Park JG, Lee SK, Hong IG et al. MDR1 gene expression: its effect on drug resistance to doxorubicin in human hepatocellular carcinoma cell lines. J. Natl. Cancer Inst. 1994 86 : 700 5.
10. Cavalli F, Tschopp L, Gerber A, Sonntag RW, Ryssel HJ, Brunner KW. Therapeutic results using VP 16-213 alone or in combination with 5-fluorouracil in liver cancer (hepatoma). Schweiz Med. Wochenschr. 1977 107 : 1960 6.
11. Yoshino M, Okazaki N, Yoshida T et al. A phase II study of etoposide in patients with hepatocellular carcinoma by the Tokyo Liver Cancer Chemotherapy Study Group. Jpn. J. Clin. Oncol. 1989 19 : 120 2.
12. Cheng AL, Chen YC, Yeh KH, Chuang SE, Chen BR, Chen DS. Chronic oral etoposide and tamoxifen in the treatment of far-advanced hepatocellular carcinoma. Cancer 1996 77 : 872 7.
13. Melia WM, Johnson PJ, Williams R. Induction of remission in hepatocellular carcinoma. A comparison of VP 16 with adriamycin. Cancer 1983 51 : 206 10.
14. Plosker GL, Faulds D. Epirubicin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in cancer chemotherapy. Drugs 1993 45 : 788 856.
15. Hochster HS, Green MD, Speyer J, Fazzini E, Blum R, Muggia FM. 4′Epidoxorubicin (epirubicin): activity in hepatocellular carcinoma. J. Clin. Oncol. 1985 3 : 1535 40.
16. Dobbs NA, Twelves CJ, Rizzi P et al. Epirubicin in hepatocellular carcinoma: pharmacokinetics and clinical activity. Cancer Chemother. Pharmacol. 1994 34 : 405 10.
17. Bobbio-Pallavicini E, Porta C, Moroni M et al. Epirubicin and etoposide combination chemotherapy to treat hepatocellular carcinoma patients: a phase II study. Eur. J. Cancer 1997 33 : 1784 8.
18. The Cancer of the Liver Italian Program Investigators. A new prognostic system for hepatocellular carcinoma: a retrospective study of 435 patients: the Cancer of the Liver Italian Program (CLIP) investigators. Hepatology 1998 28 : 751 5.
19. Kurokawa Y, Matoba R, Nagano H et al. Molecular prediction of response to 5-fluorouracil and interferon-{alpha} combination chemotherapy in advanced hepatocellular carcinoma. Clin. Cancer Res. 2004 10 : 6029 38.
20. Iavarone M, Lampertico P, Seletti C et al. The clinical and pathogenetic significance of estrogen receptor-beta expression in chronic liver diseases and liver carcinoma. Cancer 2003 98 : 529 34.
21. Villa E, Dugani A, Moles A et al. Variant liver estrogen receptor transcripts already occur at an early stage of chronic liver disease. Hepatology 1998 27 : 983 8.
22. Villa E, Moles A, Ferretti I et al. Natural history of inoperable hepatocellular carcinoma: estrogen receptors' status in the tumor is the strongest prognostic factor for survival. Hepatology 2000 32 : 233 8.
23. Cantarini MC, Trevisani F, Morselli-Labate AM et al. Effect of the etiology of viral cirrhosis on the survival of patients with hepatocellular carcinoma. Am. J. Gastroenterol. 2006 101 : 91 8.
24. Yeo W, Mo FKF, Chan SI et al. Hepatitis B viral load predicts survival of HCC patients undergoing systemic chemotherapy. Hepatology 2007 45 : 1382 9.
25. Chung Y-H, Song IH, Song B-C et al. Combined therapy consisting of intraarterial cisplatin infusion and systemic interferon-α for hepatocellular carcinoma patients with major portal vein thrombosis or distant metastasis. Cancer 2000 88 : 1986 91.
26. Campbell TN, Howell SB, Pfeifle CE, Wung WE, Bookstein J. Clinical pharmacokinetics of intraarterial cisplatin in humans. J. Clin. Oncol. 1983 1 : 755 62.
27. Yeh C-N, Chen M-F, Jeng L-B. Resection of peritoneal implantation from hepatocellular carcinoma. Ann. Surg. Oncol. 2002 9 : 863 8.